Taro Pharmaceutical Industries Future Growth
Future criteria checks 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Taro Pharmaceutical Industries.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Pharmaceuticals earnings growth | 21.1% |
| Revenue growth rate | n/a |
| Future return on equity | n/a |
| Analyst coverage | None |
| Last updated | n/a |
Recent future growth updates
Recent updates
Taro Pharmaceutical Industries Ltd. Is An Overlooked Opportunity
Dec 12Taro Pharmaceutical: Sun Pharma Deal Uncertain, No Discernible Value Beyond NAV (Rating Downgrade)
Aug 16Taro Pharmaceutical: Potential Value In Sun Pharma Offer
Jun 02Taro Pharmaceutical: Stagnating Growth At 1.6% Trailing Earnings Yield, Rate Hold
Feb 24Taro Pharmaceutical GAAP EPS of $0.19 misses by $0.68, revenue of $139.2M misses by $23.92M
Jan 24Taro Pharmaceutical Non-GAAP EPS of $0.66 misses by $0.18, revenue of $130.5M misses by $30.52M
Oct 28Taro Pharmaceutical hits 52-week low; down 28% YTD
Aug 15Taro Pharmaceutical Non-GAAP EPS of $1.09 beats by $0.24, revenue of $156.7M beats by $6.8M
Jul 27Taro Pharmaceutical: 10%+ Projected Earnings Yield Is A Strong Calling Card
Jul 14We Think Taro Pharmaceutical Industries' (NYSE:TARO) Healthy Earnings Might Be Conservative
Aug 03
A Look At Taro Pharmaceutical Industries' (NYSE:TARO) Share Price Returns
Jan 26
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Taro Pharmaceutical Industries has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 3/31/2024 | 618 | 41 | N/A | N/A | 1 |
| 12/31/2023 | 611 | 46 | 88 | 143 | N/A |
| 9/30/2023 | 593 | 33 | 97 | 125 | N/A |
| 6/30/2023 | 575 | 21 | 75 | 98 | N/A |
| 3/31/2023 | 573 | 25 | 14 | 32 | N/A |
| 12/31/2022 | 570 | 46 | 2 | 16 | N/A |
| 9/30/2022 | 569 | 65 | -198 | -188 | N/A |
| 6/30/2022 | 571 | 91 | -271 | -261 | N/A |
| 3/31/2022 | 561 | 58 | -171 | -159 | N/A |
| 12/31/2021 | 566 | 1 | -161 | -149 | N/A |
| 9/30/2021 | 568 | 8 | 72 | 86 | N/A |
| 6/30/2021 | 578 | 29 | 10 | 26 | N/A |
| 3/31/2021 | 549 | -387 | 29 | 46 | N/A |
| 12/31/2020 | 576 | -303 | 22 | 44 | N/A |
| 9/30/2020 | 583 | -268 | 76 | 100 | N/A |
| 6/30/2020 | 601 | -257 | 228 | 253 | N/A |
| 3/31/2020 | 645 | 244 | 243 | 272 | N/A |
| 12/31/2019 | 650 | 248 | 252 | 281 | N/A |
| 9/30/2019 | 678 | 274 | 258 | 289 | N/A |
| 6/30/2019 | 677 | 281 | 291 | 324 | N/A |
| 3/31/2019 | 670 | 282 | 293 | 324 | N/A |
| 12/31/2018 | 665 | 310 | 331 | 363 | N/A |
| 9/30/2018 | 644 | 234 | 313 | 343 | N/A |
| 6/30/2018 | 655 | 224 | 304 | 333 | N/A |
| 3/31/2018 | 662 | 211 | 294 | 324 | N/A |
| 12/31/2017 | 683 | 208 | 313 | 343 | N/A |
| 9/30/2017 | 748 | 330 | N/A | 384 | N/A |
| 6/30/2017 | 807 | 401 | N/A | 454 | N/A |
| 3/31/2017 | 879 | 457 | N/A | 438 | N/A |
| 12/31/2016 | 948 | 489 | N/A | 476 | N/A |
| 9/30/2016 | 986 | 538 | N/A | 458 | N/A |
| 6/30/2016 | 969 | 547 | N/A | 383 | N/A |
| 3/31/2016 | 951 | 541 | N/A | 395 | N/A |
| 12/31/2015 | 930 | 579 | N/A | 454 | N/A |
| 9/30/2015 | 909 | 532 | N/A | 440 | N/A |
| 6/30/2015 | 948 | 542 | N/A | 439 | N/A |
| 3/31/2015 | 863 | 485 | N/A | 407 | N/A |
| 12/31/2014 | 806 | 422 | N/A | 277 | N/A |
| 9/30/2014 | 782 | 395 | N/A | 294 | N/A |
| 6/30/2014 | 736 | 348 | N/A | 329 | N/A |
| 3/31/2014 | 759 | 361 | N/A | 358 | N/A |
| 12/31/2013 | 737 | 321 | N/A | 349 | N/A |
| 9/30/2013 | 709 | 294 | N/A | 327 | N/A |
| 6/30/2013 | 665 | 263 | N/A | 294 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if TARO's forecast earnings growth is above the savings rate (2.3%).
Earnings vs Market: Insufficient data to determine if TARO's earnings are forecast to grow faster than the US market
High Growth Earnings: Insufficient data to determine if TARO's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if TARO's revenue is forecast to grow faster than the US market.
High Growth Revenue: Insufficient data to determine if TARO's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if TARO's Return on Equity is forecast to be high in 3 years time